In particular, in HER2-positive breast cancer, MUC4 expression impairs trastuzumab efficacy by masking the binding epitope in the HER2 molecule and is an independent biomarker of poor survival in patients treated with adjuvant trastuzumab. Here, ERBB2 is linked to breast cancer.